Vicore Pharma Holding AB (publ) (VICO.ST) Stock Analysis & Winston Score

Vicore Pharma is a Swedish biotech company that develops medicines for serious lung diseases. Its main focus is a drug called tozorakimab, which targets conditions like idiopathic pulmonary fibrosis (IPF), a disease where lung tissue becomes permanently scarred. The company partners with AstraZeneca, which licenses and funds development of tozorakimab, giving Vicore access to a much larger partner's resources and global reach. Vicore earns money primarily through licensing agreements and milestone payments from AstraZeneca rather than selling products directly to patients. The company is based in Gothenburg, Sweden, and operates mainly in Europe with clinical trials running internationally. With a market cap around $2.6 billion but deeply negative operating margins, Vicore is a pre-revenue-stage company that burns cash while running trials — the key risk is that tozorakimab must succeed in late-stage clinical trials to justify its valuation, and drug trial failures are common in biotech.